Novartis Delivered Growth Across all Divisions in Second Quarter
- Group net sales increased 1% (+3% cc) versus year ago to USD 14.5 billion in second quarter, up 2% (+4% cc) to USD 28.5 billion in first half
- Core operating income was USD 3.8 billion (-2%, +2% cc) in second quarter, USD 7.5 billion (0%, +4% cc) in first half
- Core EPS was USD 1.30 (-4%, +1% cc) in second quarter, USD 2.62 (+1%, +5% cc) in first half
- Free cash flow was USD 1.8 billion in second quarter, USD 3.1 billion in first half.
- Excluding impact of patent expiries, underlying performance demonstrates strong growth
- Underlying net sales growth was 8% (cc) in second quarter and first half
- Underlying core operating income up 18% (cc) in second quarter and up 17% (cc) in first half.
- Strong innovation continued, reinforcing growth prospects
- Phase III study of AIN457 in psoriasis demonstrated superiority to current standard of care
- Lucentis received EU approval for myopic choroidal neovascularization; FDA approved Ilaris in systemic juvenile idiopathic arthritis, Exelon Patch in severe Alzheimer's disease and Simbrinza Suspension in glaucoma
- RLX030 granted Breakthrough Therapy designation from FDA in acute heart failure.
- Successful execution on growth products and performance in Emerging Growth Markets
- Growth products including Gilenya, Afinitor, Tasigna, Galvus and Jakavi grew 13% to USD 4.5 billion, accounting for 31% of Group net sales in second quarter; achieved net sales of USD 8.7 billion (+14%) in first half
- Emerging Growth Markets up 11% (cc) in the second quarter, led by China (+25% cc), Russia (+18% cc) and South Korea (+16% cc).
- 2013 Group outlook increased: sales upgraded to low-single digit growth versus year ago (cc); core operating income improved to low-single digit decline (cc).
 Core results, constant currencies and free cash flow are non-IFRS measures. An explanation of these non-IFRS measures and reconciliation tables can be found beginning on page 42 of the Condensed Financial Report.
 Growth products are defined on page 2.
Commenting on the results, Joseph Jimenez, CEO of Novartis, said: "Novartis delivered a solid second quarter, resulting in a good first half in 2013. Successful execution on growth brands allowed us to navigate patent expiries and new competition, while deepening our footprint in Emerging Growth Markets such as China and Russia. Our underlying business showed strong growth behind significant innovation, with sales up 8% and core operating income up 17% in constant currencies in the first half excluding the impact of generics."
The latest appointments and promotions across the pharmaceutical supply chain.
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts.
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers?
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government.
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance